First Allied Advisory Services’s Galectin Therapeutics GALT Stock Holding History

First Allied Advisory Services’s Portfolio GALT Stock Details GALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-35,000	Closed	-$223K	–	1208
2018 Q2	$223K	Buy	+35,000	New	+$170K	0.01%	1017

Other funds holding GALT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DADC

D.A. Davidson & Co Great Falls, Montana $18.1B AUM 24.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Advisor Group Phoenix, Arizona $14.5B AUM 24.86% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

FFA

First Foundation Advisors Irvine, California $2.48B AUM 18.56% 1-Year Est. Return

BCA

Benchmark Capital Advisors New York $101M AUM 0.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

First Allied Advisory Services's GALT Position: Q3 2018 in Review

First Allied Advisory Services sold out of Galectin Therapeutics (GALT) in Q3 2018, closing a stake of 35,000 shares — an estimated $223K sold.

First Allied Advisory Services first reported a position in GALT in Q2 2018 and held it in 1 quarter. The position peaked at $223K in Q2 2018. 60 funds tracked by Wall St. Rank hold GALT as of Q3 2018.

First Allied Advisory Services reported no remaining Galectin Therapeutics position as of Q3 2018 after selling out during the quarter.
First Allied Advisory Services sold 35,000 Galectin Therapeutics shares in Q3 2018, an estimated $223K.
First Allied Advisory Services first reported a position in Galectin Therapeutics in Q2 2018 and held it in 1 quarter.
First Allied Advisory Services's Galectin Therapeutics position peaked at $223K in Q2 2018.
60 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q3 2018.

Based on First Allied Advisory Services's 13F filing for Q3 2018, filed 14 Nov 2018.